Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2011

01-01-2011 | Original Article

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

Authors: In Hae Park, Sun Young Kim, Young-Woo Kim, Keun Won Ryu, Jun Ho Lee, Jong Seok Lee, Young-Iee Park, Noe Kyeong Kim, Sook Ryun Park

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2011

Login to get access

Abstract

Background

Although gastric cancer with isolated para-aortic lymph node (PAN) involvement is considered an advanced disease, the clinical characteristics of it have not been comprehensively elucidated.

Patients and methods

We reviewed the medical records of 1,277 patients received palliative chemotherapy with advanced gastric cancer according to metastatic sites: PAN-only metastasis, single organ metastasis other than PAN, and multiple organ metastasis. Time to other organ metastasis (TTOM) was determined only in PAN-only metastasis group as the time interval between initial diagnosis of recurrence or de novo metastasis and confirming distant metastasis beyond PAN area.

Results

The median overall survival (OS) of patients with PAN-only metastasis was significantly longer than that of patients with single organ metastasis other than PAN or multiple organ metastasis (13.8 months vs. 11.4 months vs. 8.4 months; P < 0.001). In the PAN-only metastasis group, patients with recurrent diseases showed longer TTOM beyond the PAN area (10.7 vs. 7.7 months; P = 0.037) and OS (23.8 vs. 12.8 months; P = 0.010) than those with de novo metastatic disease and it was validated by multivariate analysis.

Conclusion

Patients with isolated PAN metastasis showed an excellent prognosis compared with patients with metastasis at other sites and it was primarily evident in patients with recurrent PAN metastasis.
Literature
2.
go back to reference Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW et al (2002) Cancer incidence in Korea. Cancer Res Treat 34:405–408 Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW et al (2002) Cancer incidence in Korea. Cancer Res Treat 34:405–408
3.
go back to reference D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240:808–816CrossRefPubMed D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240:808–816CrossRefPubMed
4.
go back to reference Yoo CH, Noh SH, Shin DW, Choi SH, Min JS (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87:236–242CrossRefPubMed Yoo CH, Noh SH, Shin DW, Choi SH, Min JS (2000) Recurrence following curative resection for gastric carcinoma. Br J Surg 87:236–242CrossRefPubMed
5.
go back to reference Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA (2007) Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110:2186–2190CrossRefPubMed Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA (2007) Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer 110:2186–2190CrossRefPubMed
6.
go back to reference Takashima S, Kosaka T (2005) Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surg Today 35:425–431CrossRefPubMed Takashima S, Kosaka T (2005) Results and controversial issues regarding a para-aortic lymph node dissection for advanced gastric cancer. Surg Today 35:425–431CrossRefPubMed
7.
go back to reference Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T et al (2008) Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 13:132–137CrossRefPubMed Yonemura Y, Wu CC, Fukushima N, Honda I, Bandou E, Kawamura T et al (2008) Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 13:132–137CrossRefPubMed
8.
go back to reference Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoro A, Kurita A et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359:453–462CrossRefPubMed Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoro A, Kurita A et al (2008) D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359:453–462CrossRefPubMed
9.
go back to reference Nakane Y, Okamura S, Masuya Y, Okumura S, Akehira K, Hioki K (1998) Incidence and prognosis of para-aortic lymph node metastasis in gastric cancer. Hepatogastroenterology 45:1901–1906PubMed Nakane Y, Okamura S, Masuya Y, Okumura S, Akehira K, Hioki K (1998) Incidence and prognosis of para-aortic lymph node metastasis in gastric cancer. Hepatogastroenterology 45:1901–1906PubMed
10.
go back to reference Isozaki H, Okajima K, Fujii K, Nomura E, Izumi N, Mabuchi H et al (1999) Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 46:549–554PubMed Isozaki H, Okajima K, Fujii K, Nomura E, Izumi N, Mabuchi H et al (1999) Effectiveness of paraaortic lymph node dissection for advanced gastric cancer. Hepatogastroenterology 46:549–554PubMed
11.
go back to reference Lee JH, Paik YH, Lee JS, Song HJ, Ryu KW, Kim CG et al (2006) Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan. Ann Surg Oncol 13:1163–1167CrossRefPubMed Lee JH, Paik YH, Lee JS, Song HJ, Ryu KW, Kim CG et al (2006) Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan. Ann Surg Oncol 13:1163–1167CrossRefPubMed
12.
go back to reference Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1:10–24CrossRefPubMed Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1:10–24CrossRefPubMed
13.
go back to reference Kudo R, Ebihara S, Fujii M, Kaneko A, Noguchi S, Uchida A et al (2003) Classification of regional lymph nodes in Japan. Int J Clin Oncol 8:248–275CrossRef Kudo R, Ebihara S, Fujii M, Kaneko A, Noguchi S, Uchida A et al (2003) Classification of regional lymph nodes in Japan. Int J Clin Oncol 8:248–275CrossRef
14.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205–216
15.
go back to reference Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH et al (2008) Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61:301–307CrossRefPubMed Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH et al (2008) Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61:301–307CrossRefPubMed
16.
go back to reference Fuse N, Fukuda H, Yamada Y, Sawaki A, Koizumi W, Suzuki Y et al (2009) Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 27:4514 Fuse N, Fukuda H, Yamada Y, Sawaki A, Koizumi W, Suzuki Y et al (2009) Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 27:4514
17.
go back to reference Pozzo C, Ohashi Y, On behalf of the GASTRIC (2009) Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol 27:4550 Pozzo C, Ohashi Y, On behalf of the GASTRIC (2009) Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol 27:4550
18.
go back to reference Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ et al (2007) Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 37:30–37CrossRefPubMed Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ et al (2007) Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol 37:30–37CrossRefPubMed
19.
go back to reference Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH et al (2006) Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol 57:289–294CrossRefPubMed Park SH, Lee WK, Chung M, Bang SM, Cho EK, Lee JH et al (2006) Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol 57:289–294CrossRefPubMed
20.
go back to reference Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891CrossRefPubMed Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC et al (2007) Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 18:886–891CrossRefPubMed
21.
go back to reference Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403CrossRefPubMed Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403CrossRefPubMed
22.
go back to reference Sun J, Sun YH, Zeng ZC, Qin XY, Zeng MS, Chen B et al (2009) Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys (Epub ahead) Sun J, Sun YH, Zeng ZC, Qin XY, Zeng MS, Chen B et al (2009) Consideration of the role of radiotherapy for abdominal lymph node metastases in patients with recurrent gastric cancer. Int J Radiat Oncol Biol Phys (Epub ahead)
Metadata
Title
Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement
Authors
In Hae Park
Sun Young Kim
Young-Woo Kim
Keun Won Ryu
Jun Ho Lee
Jong Seok Lee
Young-Iee Park
Noe Kyeong Kim
Sook Ryun Park
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1296-y

Other articles of this Issue 1/2011

Cancer Chemotherapy and Pharmacology 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine